Turnstone Biologics Statistics
Total Valuation
TSBX has a market cap or net worth of $8.10 million. The enterprise value is -$19.64 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSBX has 23.14 million shares outstanding. The number of shares has increased by 99.23% in one year.
| Current Share Class | 23.14M |
| Shares Outstanding | 23.14M |
| Shares Change (YoY) | +99.23% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 3.83% |
| Owned by Institutions (%) | 24.29% |
| Float | 14.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.26 |
| P/TBV Ratio | 0.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.17, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.17 |
| Quick Ratio | 3.53 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -108.87% and return on invested capital (ROIC) is -68.12%.
| Return on Equity (ROE) | -108.87% |
| Return on Assets (ROA) | -59.92% |
| Return on Invested Capital (ROIC) | -68.12% |
| Return on Capital Employed (ROCE) | -229.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.06M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TSBX has paid $37,000 in taxes.
| Income Tax | 37,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.60% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -88.60% |
| 50-Day Moving Average | 0.38 |
| 200-Day Moving Average | 0.74 |
| Relative Strength Index (RSI) | 45.71 |
| Average Volume (20 Days) | 102,917 |
Short Selling Information
The latest short interest is 378,125, so 1.63% of the outstanding shares have been sold short.
| Short Interest | 378,125 |
| Short Previous Month | 434,309 |
| Short % of Shares Out | 1.63% |
| Short % of Float | 2.69% |
| Short Ratio (days to cover) | 3.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | -56.93M |
| Operating Income | -73.32M |
| Pretax Income | -75.09M |
| Net Income | -70.84M |
| EBITDA | -71.48M |
| EBIT | -73.32M |
| Earnings Per Share (EPS) | -$3.07 |
Full Income StatementBalance Sheet
The company has $28.93 million in cash and $1.19 million in debt, giving a net cash position of $27.74 million or $1.20 per share.
| Cash & Cash Equivalents | 28.93M |
| Total Debt | 1.19M |
| Net Cash | 27.74M |
| Net Cash Per Share | $1.20 |
| Equity (Book Value) | 31.47M |
| Book Value Per Share | 1.36 |
| Working Capital | 26.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$67.44 million and capital expenditures -$229,000, giving a free cash flow of -$67.67 million.
| Operating Cash Flow | -67.44M |
| Capital Expenditures | -229,000 |
| Free Cash Flow | -67.67M |
| FCF Per Share | -$2.92 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |